Novel Nomogram That Predicts Aggressive Disease and Treatment Failure Among African-American Men with Prostate Cancer.

摘要

Prostate cancer (PCa) has greatest incidence and mortality among African American (AA) as compared to their European American (EA) counterparts in the US. This disparity has been attributed to a number of factors including access to care, screening patterns, and behavior. More recent data suggest that genetic/biologic factors may at least in part contribute to more aggressive disease in AA men. Using the SCORE database, we studied PCa outcomes in AA vs. EA men after radical prostatectomy. We showed that AA race was a predictor of worse biochemical failure in patients with pathologic Gleason score less than or equal to 6 or low-grade disease and favorable pathologic features (Yamoah et, al., 2014). Next, immunohistochemistry for 20 biomarkers was undertaken on the FFPE tumors of 45 EA and 55 AA men within the SCORE database. To date, 6 biomarkers have been analyzed including TMPRSS2-ERG, AMACR, PSMA, RB, c-Myc, and AR. We observed statistically significant differences in biomarker expression between EA vs AA for AMACR (p=0.004), c-myc (p=0.005), and AR (p=0.002).